# Anti-PD-L1 and SAbR for Ovarian Cancer

> **NCT03312114** · PHASE2 · TERMINATED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 5 (actual)

## Conditions studied

- Recurrent Epithelial Cancer of Ovary
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03312114
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-09
- **Primary completion:** 2019-03-19
- **Final completion:** 2019-03-19
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2020-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312114, "Anti-PD-L1 and SAbR for Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03312114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*